The characteristics of 51 CP-CML patients on TKI and 24 healthy controls in this study
| Characteristics . | Patients, N = 51 . | Healthy controls, N = 24 . |
|---|---|---|
| Age, median (range) | 52 (27-75) | 41 (29-70) |
| Gender (M/F) | 33/18 | 13/11 |
| TKI | N/A | |
| Imatinib | 26 | |
| Dasatinib | 13 | |
| Nilotinib | 12 |
| Characteristics . | Patients, N = 51 . | Healthy controls, N = 24 . |
|---|---|---|
| Age, median (range) | 52 (27-75) | 41 (29-70) |
| Gender (M/F) | 33/18 | 13/11 |
| TKI | N/A | |
| Imatinib | 26 | |
| Dasatinib | 13 | |
| Nilotinib | 12 |
NA, not applicable.